Janielle P Maynard
Overview
Explore the profile of Janielle P Maynard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manoharan V, Adegbayi O, Maynard J
Purinergic Signal
. 2024 Oct;
PMID: 39387963
P2 purinergic receptor expression is dysregulated in multiple cancer subtypes and is associated with worse outcomes. Studies identify roles for P2 purinergic receptors in tumor cells that drive disease aggressiveness....
2.
Arunachalam A, Samuel S, Mani A, Maynard J, Stayer K, Dybbro E, et al.
Am J Physiol Gastrointest Liver Physiol
. 2023 Sep;
325(5):G471-G491.
PMID: 37697947
The liver plays a significant role in regulating a wide range of metabolic, homeostatic, and host-defense functions. However, the impact of liver injury on the host's ability to control bacteremia...
3.
Maynard J, Godwin T, Lu J, Vidal I, Lotan T, De Marzo A, et al.
Prostate
. 2022 Aug;
82(16):1505-1519.
PMID: 35971807
Background: Black men are two to three times more likely to die from prostate cancer (PCa) than White men. This disparity is due in part to discrepancies in socioeconomic status...
4.
Maynard J, Sfanos K
Purinergic Signal
. 2022 Jun;
18(3):267-287.
PMID: 35687210
P2 purinergic receptors are involved in the normal function of the kidney, bladder, and prostate via signaling that occurs in response to extracellular nucleotides. Dysregulation of these receptors is common...
5.
Peiffer L, Hicks J, Sosa R, De Marzo A, Sfanos K, Maynard J
Front Oncol
. 2022 May;
12:877536.
PMID: 35574356
The 5-year survival rate for patients diagnosed with distant metastatic prostate cancer in the United States is 30.6%. Therefore, there is a great need to develop model systems to study...
6.
Mendes A, Lu J, Kaur H, Zheng S, Xu J, Hicks J, et al.
Cancer
. 2022 Mar;
128(12):2269-2280.
PMID: 35333400
Background: B7 homolog 3 (B7-H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD-L1. Immunotherapies (antibodies, antibody-drug conjugates,...
7.
Lopez-Bujanda Z, Haffner M, Chaimowitz M, Chowdhury N, Venturini N, Patel R, et al.
Nat Cancer
. 2022 Feb;
2(8):803-818.
PMID: 35122025
Unlike several other tumor types, prostate cancer rarely responds to immune checkpoint blockade (ICB). To define tumor cell intrinsic factors that contribute to prostate cancer progression and resistance to ICB,...
8.
Maynard J, Lu J, Vidal I, Hicks J, Mummert L, Ali T, et al.
J Pathol
. 2021 Oct;
256(2):149-163.
PMID: 34652816
Prostate cancer (PCa) remains a leading cause of cancer-related deaths in American men and treatment options for metastatic PCa are limited. There is a critical need to identify new mechanisms...
9.
Shrestha E, Coulter J, Guzman W, Ozbek B, Hess M, Mummert L, et al.
Proc Natl Acad Sci U S A
. 2021 Aug;
118(32).
PMID: 34341114
Prostate adenocarcinoma is the second most commonly diagnosed cancer in men worldwide, and the initiating factors are unknown. Oncogenic TMPRSS2:ERG (ERG+) gene fusions are facilitated by DNA breaks and occur...
10.
Vidal I, Zheng Q, Hicks J, Chen J, Platz E, Trock B, et al.
PLoS One
. 2021 Jun;
16(6):e0241934.
PMID: 34191807
GSTP1 is a member of the Glutathione-S-transferase (GST) family silenced by CpG island DNA hypermethylation in 90-95% of prostate cancers. However, prostate cancers expressing GSTP1 have not been well characterized....